Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells
References (31)
- et al.
Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta
Biochem Pharmacol
(1986) - et al.
Cyclic nucleotide phosphodiesterase activities from pig coronary arteries: lack of interconvertibility of major forms
Biochim Biophys Acta
(1980) - et al.
Fluorescence investigations of calmodulin hydrophobic sites
Biochem Biophys Res Commun
(1984) - et al.
Comparative effects of calmodulin inhibitors on calmodulin's hydrophobic sites and on the activation of cyclic nucleotide phosphodiesterase by calmodulin
Biochem Pharmacol
(1987) - et al.
Cyclic AMP and cyclic GMP phosphodiesterase activities in Hodgkin's disease lymphocytes
Int J Immunopharmac
(1987) - et al.
Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues
J Biol Chem
(1982) - et al.
Purification and characterization of cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from calf liver
J Biol Chem
(1983) - et al.
Complex effects of inhibitors on cyclic GMP-stimulated cyclic nucleotide phosphodiesterase
J Biol Chem
(1983) - et al.
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
Nature (Lond)
(1976) - et al.
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
Nature (Lond)
(1980)
Endothelial cells in culture produce a vasoconstrictor substance
J Cell Physiol
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Nature (Lond)
Hormone and neurotransmitter receptor in an established vascular endothelial cell line
Stimulation of cAMP production by vasoactive agents in cultured bovine aortic and pulmonary artery endothelial cells
In Vitro
Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin
J Clin Invest
Cited by (113)
Phosphodiesterases type 2, 3 and 4 promote vascular tone in mesenteric arteries from rats with heart failure
2023, European Journal of PharmacologyRoflumilast, a cyclic nucleotide phosphodiesterase 4 inhibitor, protects against cerebrovascular endothelial injury following cerebral ischemia/reperfusion by activating the Notch1/Hes1 pathway
2022, European Journal of PharmacologyCitation Excerpt :P < 0.05 was considered statistically significant. PDE4B is the major PDE4 subtype expressed in endothelial cells (Cheng et al., 2010; Keravis et al., 2000; Lugnier and Schini, 1990). To test the involvement of PDE4 in the destruction of BBB under the condition of OGD/R, the expression of PDE4B was knocked down by a specific siRNA.
Phosphodiesterase-1 in the cardiovascular system
2022, Cellular SignallingPDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking
2021, Biochemical PharmacologyCyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?
2020, Pharmacology and TherapeuticsCitation Excerpt :The endothelium also plays a major role in vascular tone modulation and vessel permeability, thereby regulating systemic blood pressure. Endothelial cells express PDE2, PDE3, PDE4 and PDE5, depending on the vascular bed and species (Keravis, Komas, & Lugnier, 2000; Keravis, Silva, Favot, & Lugnier, 2006; Lugnier & Schini, 1990). In heart failure (HF), endothelial dysfunction has a major effect on PDE3 function, and PDE3 inhibition restores functional relaxation after β-adrenoceptor stimulation (Hubert et al., 2014).
Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families
2017, Cellular Signalling
- †
Present address: Baylor College of Medicine, Center for Experimental Therapeutics, One Baylor Plaza, Houston, TX 77030, U.S.A.